• Anemoside B4 Inhibits Macrophage NLRP3 Inflammasome in Colit

  2026-07-22

  This study reveals that Anemoside B4 (AB4) alleviates DSS-induced colitis by targeting CD1d-dependent NLRP3 inflammasome activation in macrophages. The findings clarify AB4's anti-inflammatory mechanism, highlighting the AKT-STAT1-PRDX1-NF-κB axis and offering new insight into inflammation research and NF-κB pathway modulation.

• Deferiprone for Iron Modulation: Applied Workflows & Innovat

  2026-07-22

  Deferiprone (3-hydroxy-1,2-dimethylpyridin-4-one) is transforming iron metabolism research through selective chelation and robust protocol adaptability. Explore advanced workflows, troubleshooting insights, and the latest experimental revelations that make this APExBIO compound a cornerstone in cancer and metabolic studies.

• Lopinavir (ABT-378): Advanced Workflows for HIV Protease Inh

  2026-07-21

  Lopinavir (ABT-378) from APExBIO excels in HIV protease inhibition, offering reliable potency even in serum-rich and mutant-challenged environments. Explore actionable protocols, cross-pathogen applications, and troubleshooting strategies that set a new benchmark for antiviral compound research.

• Oleic Acid (C18:1(9Z)): Advanced Mechanistic Roles in Lipid

  2026-07-21

  Discover how Oleic Acid (C18:1(9Z)) drives innovation in lipid metabolism research and complex signaling assays. This article uniquely explores its mechanistic interplay, protocol nuances, and translational value beyond standard workflows.

• Nebivolol Hydrochloride: Selective β1-Adrenoceptor Antagonis

  2026-07-20

  Nebivolol hydrochloride is a potent, highly selective β1-adrenoceptor antagonist used in cardiovascular research. It exhibits nanomolar IC50, confirmed pathway specificity, and does not inhibit the mTOR pathway, making it invaluable for precise β1-adrenergic receptor signaling studies.

• HDAC Inhibition Reverses EBV-Induced Dedifferentiation in NP

  2026-07-20

  The referenced study uncovers how Epstein-Barr virus (EBV) drives dedifferentiation in nasopharyngeal carcinoma (NPC) via epigenetic repression of CEBPA, and demonstrates that histone deacetylase (HDAC) inhibitors can restore differentiation and suppress cancer cell plasticity in vivo. This mechanistic insight advances differentiation therapy prospects for solid tumors and provides a foundation for integrating epigenetic modulators into cancer research workflows.

• RRP Extracts Restore Hepatic Lipid Metabolism in Ischemia-Re

  2026-07-19

  The reference study demonstrates that Radix Rehmanniae Praeparata (RRP) extracts alleviate hepatic ischemia-reperfusion injury (HIRI) in mice by targeting key lipid metabolism regulators in hepatocytes. These mechanistic insights offer a rationale for therapeutic strategies addressing postoperative liver injury and advance the translational relevance of lipid metabolism research.

• Plerixafor (AMD3100): Beyond CXCR4 Antagonism in Cancer and

  2026-07-18

  Explore how Plerixafor (AMD3100) transcends CXCR4 antagonism, offering advanced capabilities in cancer metastasis inhibition and hematopoietic stem cell mobilization. This article delivers unique practical insights by integrating breakthrough findings on assay selection and translational strategies.

• Metal-Ion-Chelating L-Phe Nanostructures Overcome Tumor Immu

  2026-07-17

  This study reveals that metal-ion-chelating L-phenylalanine nanostructures, in synergy with short-term starvation, reprogram the immunosuppressive tumor microenvironment and potentiate immune checkpoint blockade in breast cancer models. The findings highlight a mechanistic breakthrough in dendritic cell activation via ion channel modulation, offering new strategies for enhancing immunotherapy efficacy.

• MOF-5 Adsorption of Merbromin and Safranin O in Wastewater R

  2026-07-17

  This study demonstrates the first use of MOF-5 for adsorptive elimination of Merbromin, a mercury dibromofluorescein disodium salt, and Safranin O from simulated and real wastewater. The findings illuminate both the effectiveness and mechanistic considerations of MOF-5 in removing pharmaceutical and dye-based pollutants under varying environmental conditions.

• ABT-199 (Venetoclax): Redefining Apoptosis in Hematologic Re

  2026-07-16

  This article explores how ABT-199 (Venetoclax) is transforming the field of apoptosis research in hematologic malignancies. By combining mechanistic insights with strategic recommendations for translational research, we highlight how selective Bcl-2 inhibition unlocks new experimental and clinical opportunities. The discussion integrates fresh findings on apoptosis pathways, competitive landscape analysis, and actionable workflow parameters, while positioning ABT-199 from APExBIO as the benchmark tool for next-generation apoptosis assays.

• Plerixafor (AMD3100): Applied Workflows and Troubleshooting

  2026-07-16

  Plerixafor (AMD3100) is the gold-standard CXCR4 antagonist, empowering both cancer and stem cell researchers to dissect and manipulate the SDF-1/CXCR4 axis. This guide translates recent experimental insights into actionable protocols, troubleshooting steps, and advanced use-cases to help you maximize reproducibility and translational impact.

• Targeting FLT3-TAZ Signaling to Overcome Drug Resistance in

  2026-07-15

  Shin et al. (2023) identify FLT3-driven signaling as a key mechanism underlying broad drug resistance in blast phase chronic myeloid leukemia (BP-CML), establishing FLT3 as a novel prognostic marker and therapeutic target. Their work demonstrates that inhibiting FLT3—alone or in combination with BCR::ABL1 TKIs—can suppress resistance, suggesting promising new directions for high-risk BP-CML treatment.

• TBST (Tris-Buffered Saline and Tween 20): Technical Lab Use

  2026-07-15

  TBST (Tris-Buffered Saline and Tween 20) addresses high background and nonspecific binding in immunoassays by providing a reliable, isotonic blocking and washing buffer. It is recommended for workflows such as Western blotting, immunofluorescence, and immunohistochemistry, but should not be used in applications sensitive to non-ionic detergents.

• DRD4 Drives Chemo-Resistance via PI3K/Akt/β-Catenin in Liver

  2026-07-14

  The reference study demonstrates that dopamine receptor D4 (DRD4) promotes chemo-resistance and cancer stem cell-like properties in hepatocellular carcinoma by activating the PI3K/Akt/β-catenin axis. These findings highlight DRD4 as a potential therapeutic target and underscore the relevance of PI3K pathway inhibitors in overcoming resistance in liver cancer models.

14639 records 1/976 page Next 12345 下5页 Last page